Guest Editor: 

Endocannabinoid-related compounds in gastrointestinal diseases

Marcella Pesce a, b, Alessandra D’Alessandro a, Osvaldo Borrelli b, Stefano Gigli c, Luisa Seguella c, Rosario Cuomo a, Giuseppe Esposito c, Giovanni Sarnelli a, *

a Department of Clinical Medicine and Surgery, ‘Federico II’ University of Naples, Naples, Italy
b Division of Neurogastroenterology & Motility, Great Ormond Street Hospital and University of College (UCL), London, UK
c Department of Physiology and Pharmacology ‘Vittorio Erspamer’, La Sapienza University of Rome, Rome, Italy

Received: May 29, 2017; Accepted: July 23, 2017

Introduction

– Endocannabinoid-related compounds
– The endocannabinoid system and the control of gastrointestinal motility
– The endocannabinoid system and the control of visceral sensitivity
– The endocannabinoid system and the control of intestinal inflammation
– The endocannabinoid system in gut pathophysiology
– The endocannabinoid system and functional dyspepsia
– The endocannabinoid system in irritable bowel syndrome
– The endocannabinoid system in inflammatory bowel disease
– The endocannabinoid system in liver disease
– Endocannabinoids in non-alcoholic fatty liver disease

Conclusions

Conflict of interest

Abstract

The endocannabinoid system (ECS) is an endogenous signalling pathway involved in the control of several gastrointestinal (GI) functions at both peripheral and central levels. In recent years, it has become apparent that the ECS is pivotal in the regulation of GI motility, secretion and sensitivity, but endocannabinoids (ECs) are also involved in the regulation of intestinal inflammation and mucosal barrier permeability, suggesting their role in the pathophysiology of both functional and organic GI disorders. Genetic studies in patients with irritable bowel syndrome (IBS) or inflammatory bowel disease have indeed shown significant associations with polymorphisms or mutation in genes encoding for cannabinoid receptor or enzyme responsible for their catabolism, respectively. Furthermore, ongoing clinical trials are testing EC agonists/antagonists in the achievement of symptomatic relief from a number of GI symptoms. Despite this evidence, there is a lack of supportive RCTs and relevant data in human beings, and hence, the possible therapeutic application of these compounds is raising ethical, political and economic concerns. More recently, the identification of several EC-like compounds able to modulate ECS function without the typical central side effects of cannabimimetics has paved the way for emerging peripherally acting drugs. This review summarizes the possible mechanisms linking the ECS to GI disorders and describes the most recent advances in the manipulation of the ECS in the treatment of GI diseases.

Keywords: endocannabinoid system, gastrointestinal pathophysiology, functional gastrointestinal disorders, non-alcoholic steatohepatitis, inflammatory bowel disease

Introduction

Cannabis sativa plant is the most commonly used illicit drug for recreational purposes worldwide, with estimated 16 million users in the United States [1, 2]. At present, many patients use cannabis anecdotally to achieve symptomatic relief from a wide variety of symptoms, commonly of GI origin, particularly nausea and pain [3–5]. The therapeutic efficacy of cannabis in the treatment of GI dysfunction relies on the fact that the GI tract is endowed with cannabino-

*Correspondence to: Giovanni SARNELLI, M.D., Ph.D.
E-mail: sarnelli@unina.it

© 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

doi: 10.1111/jcmm.13359
and degrading enzymes, they embody the endocannabinoid system (ECS), a ubiquitous and complex system involved in the control of gut homeostasis. Since first coined in 1995 [8], the term ‘endocannabinoids’ (ECs) has been enlarged to a number of recently, yet only partially, identified endogenous ligands, such as 2-arachidonoylglycerol ether (noladin ether), N-arachidonoyl-dopamine (NADA) and O-arachidonoylthanolamine (virodhamine) [9]. In recent years, several lipid-derived mediators, closely resembling typical ECs, have been described, raising questions on the different pathophysiological role of these compounds [10–13]. These analogues (namely N-linoleylethanolamine (LEA), N-oleylethanolamine (OEA), N-palmitoylethanolamine (PEA) and N-stearoylethanolamine (SEA)) are structurally related to classical ECs and have been shown to act synergistically, either enhancing the effects of prototypic ECs (the so-called entourage effect) or displaying unique effects (see the ‘Endocannabinoid-related compounds’ section). An overview of the principal ECs and of the enzymes responsible for their metabolism is proposed in Figure 1. Different from other transmitters, the ECs and their congeners are not stored in intracytoplasmic vesicles, but synthesized from membrane precursors in an ‘on-demand’ fashion [13]. After their release into the extracellular space, these short-lived compounds are rapidly removed from membrane transporters and degraded by specific enzymes (Fig. 1) [14]. The ECs are able to exert their multifaceted activities by binding a large number of receptors that have not been fully identified, so far. The best-characterized receptors are cannabinoid receptors 1 and 2 (CB1 and CB2), two G-protein-coupled receptors expressed in both peripheral and central nervous systems, as well as by a number of non-neural

Fig. 1 Schematic overview of the enzymes involved in EC metabolism. Anandamide (AEA) and 2-acylglycerol (2-AG) are the two best-recognized stereotypical ECs. Both are synthetized by hydrolysis from membrane lipid precursors, namely N-arachidonoyl-phosphatidylethanolamine (NAPE) and phosphatidylinositol 4,5-bisphosphate (PIP2) for AEA and 2-AG, respectively. Both AEA and 2-AG, after the binding with CB receptors, are rapidly removed by membrane transporters and converted into arachidonic acid by fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MAGL), respectively.

© 2017 The Authors. Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
CB1 is responsible for the classical psychotropic effects of marijuana and is mainly expressed in the CNS [17]. In the GI tract, CB1 is expressed in both myenteric and submucosal plexuses of the enteric nervous system (ENS), mostly by motoneurons, interneurons and primary afferent neurons but also by epithelial cells [18]. Conversely, CB2 predominantly shows a peripheral distribution, with the highest rate of expression on immune cells [19, 20], but it is also found on enteric neurons [21]. In rodent models, CB2 appears to be expressed by intestinal epithelial cells; however, this evidence has not been confirmed in both other animal models and human beings [22–24]. As mentioned above, ECs and their related compounds exhibit several non-CB1/CB2-mediated effects by binding other receptors with different affinity. The orphan G-protein-coupled receptor 55 (GPR55), identified in 1999, has been proposed as the third CB receptor, and although it has been found in the jejunum, ileum and colon, its distribution has not been extensively studied [25]. One of the best-characterized non-CB receptors for ECs is the transient receptor potential vanilloid type 1 (TRPV1), mainly located on the primary afferent nerve fibres [26]. Originally identified as receptors for the capsaicin [27], TRPV1 receptors are known for being activated by NADA and AEA as effectively as capsaicin [28]. AEA is a full agonist on TRPV1 receptors, but it also exerts indirect effects by binding CB1 [29]. Furthermore, a number of ECs have been shown to bind peroxisome proliferator-activated receptors (PPARs). In vitro studies showed that AEA, noladin and virodhamine are receptor agonists to PPARα, while 2-AG binds to PPARβ/δ [30]. Taken together, the bewildering redundancy of the ECS and the different sites of action of the ECs account for the great variety of actions exhibited by these compounds in vivo.

**Endocannabinoid-related compounds**

EC-like compounds, such as N-acylethanolamides (NAEs), have a close structural resemblance with classical ECs, but display no activity on CB receptors [10, 31, 32]. However, these compounds share some biological activities and similar biosynthetic pathways of those of typical ECs, particularly AEA. AEA synthesis is, indeed, coupled with the formation of PEA, OEA and LEA [10, 33, 34]. Although OEA and PEA do not directly activate cannabinoid receptors, they are thought to indirectly potentiate ECS signalling via the ‘entourage effect’ by either competing with stereotypical ECs for enzymatic degradation or increasing their receptor binding affinity [10] (Fig. 2). PEA and OEA are, indeed, both substrates of FAAH, the enzyme responsible for AEA degradation. By either competing with AEA for FAAH or inducing FAAH down-regulation [35, 36], PEA and OEA could reduce AEA catabolism and ultimately increase AEA concentrations. Furthermore, independently of FAAH, PEA and OEA are able to enhance AEA effects at TRPV1 receptors [37, 38]. OEA and PEA can activate, even if with different receptor affinity, PPARα, the G-protein-coupled receptor GPR119 and the TRPV1 [39–42]. A growing body of evidence has shown that these compounds are involved in the control of a wide variety of functions, including the control of food intake [43, 44], neuroprotection [45] and inhibition of pain and inflammation [46, 47]. PEA levels increase in inflamed tissues, possibly as a protective effect to exert its well-recognized anti-inflammatory and analgesic properties [46]. In biopsies from patients with coeliac disease, levels of both PEA and AEA were increased [48]. It has been shown that by selectively binding PPARα receptors, PEA is able to down-regulate iNOS expression and nuclear factor-κB (NF-κB) activation, and in turn the inflammation in

Fig. 2 Biosynthesis and degradation of N-acylethanolamides (NAEs) and possible points of interaction between AEA and its related compounds. Similar to AEA, N-palmitoylethanolamine (PEA) and N-oleoylethanolamine (OEA) are synthesized by N-acylphosphatidylethanolamine-specific phospholipase D (NAPE-PLD) from membrane precursors. Unlike AEA, PEA and OEA exhibit no binding affinity on CB1/CB2 receptors, but they can enhance AEA activity at TRPV1 receptors. PEA and OEA are degraded by either fatty acid amide hydrolase (FAAH) or N-acylethanolamine-hydrolysing acid amidase (NAAA). By competing with AEA for FAAH (mainly OEA) or by down-regulating FAAH expression (predominantly PEA), they can increase AEA levels.
a number of chronic inflammatory conditions, including experimen-
tal and human models of inflammatory bowel disease (IBD) [49–
51]. PEA is indeed able to significantly inhibit the expression of
S100B and Toll-like receptor 4 on enteric glial cells, thus reducing
inflammation induced by nuclear factor-κB (NFκB) by selectively
binding PPARα receptors [51]. On the contrary, OEA was able to
display antinociceptive properties in a PPAR-a-insensitive manner in
mice [47].

The endocannabinoid system and the control of
gastrointestinal motility

In both animal and human GI tract, the ECs exert marked
antipropulsive effects. This result is mainly mediated by the reduc-
tion in the release of acetylcholine via the activation of presynaptic
CB1 [18, 52–54]. However, recent evidence suggests that along
with the inhibition of acetylcholine release, the effects of the ECs
on GI motility are likely to be related to the inhibition of all the
components of the peristaltic reflex. In parallel with the inhibition
of the release of acetylcholine, in rat models CB1 agonists were
indeed able to significantly inhibit the release of both substance P
and VIP, inhibiting, respectively, both the ascending contraction
and the descending relaxation of the peristaltic reflex [55–58]. Fur-
thermore, both the deletion of the CB1 gene [55–57] and the phar-
macological blockade of these receptors [59–61] displayed prokinetic effects. Altogether, these lines of evidence seem to sug-
gest that ECs are able to significantly reduce smooth muscle con-
tactility, mainly by binding CB1. CB2 does not appear to play a
major role in the control of intestinal motility under physiological
conditions. However, studies on rodents have shown that intestinal
hypermotility due to lipopolysaccharide (LPS) administration was
abolished by CB2, but not by CB1 agonists [62]. Hence, in animal
models, CB2 agonism is more likely to inhibit intestinal motility in
pathophysiologic conditions associated with intestinal inflamma-
tion and immune activation.

The endocannabinoid system and the control of
visceral sensitivity

Undoubtedly, the most documented effect of the ECS is the con-
trol of visceral sensitivity and, although empirically grounded,
phytocannabinoid-based treatments have been used for centuries
in a number of conditions featured by chronic pain. In recent
years, several studies have elucidated the molecular mechanism
by which ECs are able to reduce visceral sensation and pain. The reduction in visceral sensitivity threshold to colorectal disten-
sion was found to be dependent on both CB1 activation and CB2
activation [63–67]. Roussaux et al. have shown that after col-
orectal distension, orally administered probiotics were able to
reduce visceral sensation in rats in a CB2-dependent fashion
[68]. Moreover, in pro-inflammatory conditions, AM124 was able to
reduce the bradykinin-induced activation of primary afferents
in wild-type but not in CB2-deficient mice [69], further support-
ing the evidence that CB2 is probably involved in the control of
visceral hypersensitivity in inflammatory conditions. In rodents,
visceral hypersensitivity due to water avoidance stress was signif-
ically associated with a decreased expression and function of
CB1, while a reciprocal increase in TRPV1 expression was found
in dorsal root ganglion (DRG) neurons [70]. CB1 and TRPV1
receptors are intimately connected, and CB1 is able to inhibit
TRPV1 activity either directly or indirectly through the cyclic
AMP–protein kinase A [71]. The treatment of DRG neurons with
anandamide, whose levels are increased in psychological stress,
was able to reproduce the changes in TRPV1 and CB1 expres-
sions, while administration of CB1 agonist and/or TRPV1 receptor
antagonist was able to prevent these effects [70]. Furthermore,
injections of corticosteroids were able to increase anandamide
expression and to reproduce the reciprocal changes in the
expression of CB1 and TRPV1 receptors [70]. Although not com-
pletely elucidated, the mechanism underlying the reduced expres-
sion of CB1 in chronic stress conditions might rely on increased
methylation of the Cnr1 gene promoter by DNMT1, which results
in epigenetic modifications of CB1 expression [72]. Collectively,
these findings indicate that the interplay between the cannabino-
id and vanilloid signalling pathways may play an important role in
stress-induced visceral hyperalgesia [73, 74]. In summary, both
CB1 activation and CB2 activation have been linked to the control
visceral sensitivity and stress-induced hyperalgesia in animal
models. The antinociceptive effects of CB1 are probably intimately
connected to a reciprocal down-regulation of TRPV1 receptors,
while CB2 is likely able to counteract the sensitizing effects of
inflammatory mediators, such as bradykinin, on peripheral end-
ings of visceral afferents.

The endocannabinoid system and the control of
intestinal inflammation

Over the past decade, many lines of evidence highlighting the
role of the ECS in intestinal inflammation have been produced in
both animal and pre-clinical models [18, 75, 76]. Although
 genetic studies failed to find any significant association between
the polymorphisms in the gene encoding for FAAH and the risk of
developing Crohn’s disease (CD), homozygosis for the muta-
tion Pro129Thr in FAAH gene was significantly associated with
development of fistulas and extra-intestinal manifestations in
patients with CD [77]. Also, in patients with ulcerative colitis
(UC), the same FAAH genetic variant led to an earlier average
onset of the inflammatory disease [77]. Furthermore, in a recent
case-control association analysis from a paediatric IBD popula-
tion, the functional CB2-R63 variant was significantly associated
with the risk of developing IBDs and also linked to a more
aggressive phenotype in both patients with CD and patients with
UC [78]. The pivotal role of the ECS in regulating intestinal
inflammation has been confirmed by the evidence that both
genetic ablation of FAAH and the pharmacological treatment with
FAAH inhibitors prevented the development of colitis in rodents [79]. In animal models, these effects are dependent on both CB1 and CB2. CB1 and CB2 agonists are indeed able to significantly reduce experimental colitis, while CB2 antagonists and CB1 knockout mice developed a more severe TNBS-induced colitis [80, 81]. Finally, it has been shown that an increase in AEA levels, induced by inhibitors of the catabolic or reuptake enzymes, significantly attenuates colitis in wild-type mice, but not in CB1- and CB2-deficient mice [82].

In human beings, ex vivo studies have demonstrated a significantly increased expression of AEA in chronic inflammatory conditions, including IBDs, diverticulitis and coeliac disease [48, 74, 75]. An overview of the reciprocal changes in CB receptors and EC levels is reported in Table 1. However, both FAAH expression and levels of AEA have been reported to be decreased or increased in colitis from different studies, pointing towards the need for further studies to fully address the role of ECS in the modulation of intestinal inflammation.

The endocannabinoid system and functional dyspepsia

Although only few studies have investigated the potential effects of ECS in FD, there is evidence suggesting that the ECS might be an intriguing target in FD treatment, as it is involved in the modulation of some of the proposed mechanisms underlying FD pathophysiology [83, 84]. In a recent study in patients with FD, Ly et al. have demonstrated a sustained increase in CB1 receptor availability in cerebral regions involved in the control of food intake and visceral sensitivity, suggesting for the first time a long-term dysfunction in ECS signalling pathways in FD [85]. However, whether this effect is a consequence of altered visceral sensitivity or of dysregulation in food intake still needs to be clarified.

The endocannabinoid system in gut pathophysiology

The homeostatic role of ECS, able to regulate GI functions peripherally and centrally, represents both a blessing and a curse, making it an appealing therapeutic target and, at the same time, a challenge in selectively modulating GI functions without altering the functionality of other organs. We will now discuss in detail the evidence produced on the role of ECS in GI disorders, namely functional dyspepsia (FD) and irritable bowel syndrome (IBS), two of the main functional gastrointestinal disorders (FGIDs), IBDs and non-alcoholic fatty liver disease (NAFLD). We will also review the most recent advances in the possible therapeutic exploitation of manipulating ECS in the treatment of these GI disorders.

**Table 1** Reported altered expression profile of endocannabinoid system (ECS) in intestinal disease

<table>
<thead>
<tr>
<th>Clinical condition</th>
<th>AEA</th>
<th>PEA</th>
<th>FAAH</th>
<th>CB1</th>
<th>CB2</th>
<th>Ref.</th>
</tr>
</thead>
<tbody>
<tr>
<td>Ileitis Mouse</td>
<td>+</td>
<td>=</td>
<td>=</td>
<td>+</td>
<td>+</td>
<td>[54, 74]</td>
</tr>
<tr>
<td>Coeliac-like atrophy Rat</td>
<td>+</td>
<td>+</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>[48]</td>
</tr>
<tr>
<td>Colitis Mouse</td>
<td>+/-</td>
<td>nd</td>
<td>+/-</td>
<td>nd</td>
<td>nd</td>
<td>[82]</td>
</tr>
<tr>
<td>IBD Human</td>
<td>+/-</td>
<td>*</td>
<td>=</td>
<td>+/-</td>
<td>+</td>
<td>[24,62]</td>
</tr>
<tr>
<td>Diverticulitis Human</td>
<td>+</td>
<td>=</td>
<td>nd</td>
<td>=</td>
<td>nd</td>
<td>[75]</td>
</tr>
<tr>
<td>FD Human</td>
<td>nd</td>
<td>nd</td>
<td>nd</td>
<td>+/-</td>
<td>*</td>
<td>[85]</td>
</tr>
<tr>
<td>IBS Human</td>
<td>nd</td>
<td>*</td>
<td>nd</td>
<td>*</td>
<td>+</td>
<td>[105]</td>
</tr>
<tr>
<td>NAFLD/NASH Human</td>
<td>+</td>
<td>nd</td>
<td>+</td>
<td>*</td>
<td></td>
<td>[116, 117, 120, 121]</td>
</tr>
</tbody>
</table>

+: increase; –: decrease; =: no significant change; nd: not determined; +/-: conflicting results; *: indirect evidence from administration of agonists/antagonists. IBD: inflammatory bowel disease; FD: functional dyspepsia; IBS: irritable bowel syndrome; NAFLD: non-alcoholic fatty liver disease; NASH: non-alcoholic steatohepatitis.

© 2017 The Authors.
Journal of Cellular and Molecular Medicine published by John Wiley & Sons Ltd and Foundation for Cellular and Molecular Medicine.
The endocannabinoid system in irritable bowel syndrome

Although the pathophysiology of IBS is still not completely understood, gut motility impairment, visceral hyperalgesia, low-grade inflammation and gut-brain axis alterations have all been associated with symptoms onset [93]; hence, the ECS may represent a new therapeutic target. As ECs are known to decrease GI motility [94, 95], dronabinol, a derivative of THC, has been tested in patients affected by diarrhoea-predominant IBS (IBS-D) showing variable results. It has been shown that this compound was effective in decreasing the colonic transit but not colonic sensitivity, and this effect was limited to those patients carrying CB1 receptor polymorphism rs806378 [96, 97]. Moreover, as the activation of CB1 may reduce GI transit, the use of its antagonist may be used to increase stool frequency in constipation-predominant IBS (IBS-C). Actually, a selective CB1 antagonist, namely rimonabant (SR141716A), was able to increase colonic motility in mice [61]. Interestingly, also the inhibition of the 2-AG synthetase DAGL using orlistat was found to normalize stool frequency in a mouse model of chronic constipation, without affecting basal motility [98]. In addition, several lines of evidence suggested that the increase in CB1 activity might lead to a reduction in visceral sensitivity [66, 99–101]. Esfandyari et al. have tested the efficacy of dronabinol in visceral sensitivity in a randomized, double-blind, placebo-controlled trial showing its ability to increase colonic compliance and relaxation in vivo [90]. However, a further study failed to find significant difference in terms of rectal compliance between dronabinol and placebo [97]. This discrepancy may be due to a different expression of CB1 in colon and rectum. Finally, several studies revealed that the ECS also participates in immune response, mainly reducing the production of inflammatory cytokines. Given the evidence for a role of low-grade inflammation in IBS, ECs may also improve IBS symptoms by decreasing the inflammatory response [102–104]. All these lines of evidence confirm that the ECS may represent a new therapeutic target in IBS; however, the risk of adverse effect still limits the use of ECs in treating FGIDs. Therefore, EC-like compounds able to modulate ECS signalling with a good safety profile and, more importantly, without central side effects appear as promising candidates in IBS treatment. Recently, a multi-centre randomized, double-blind, placebo-controlled study has shown the efficacy of anandamide and 2-AG increased intestinal permeability when apically administered on Caco-2 cells, and an in vivo study in obese mice, a model of leaky gut, showed that the CB1 antagonist rimonabant was able to reduce plasmatic LPS level, confirming the role of ECs in regulating gut permeability [107–109]. Interestingly, further studies have revealed that while CB1 mainly mediates the effects of ECs in a physiological setting, CB2 seems to assume a prevalent role during inflammatory process. Indeed, immunohistochemical studies showed that during inflammatory flares, the expression of CB2, but not of CB1, is modified and amplified [24, 62]. This evidence is very intriguing as CB2 agonists may represent a new therapeutic strategy in IBD, acting directly and specifically on inflamed tissue, thus reducing central adverse effects. Finally, a protective effect of PEA has been demonstrated in human biopsies from patients with active UC, suggesting that exogenous administration of EC-like amides may improve mucosal healing in patients with IBD [51]. As NAEs are already available for treating neuropathic pain, showing a good efficacy and safety profile, further clinical trials to evaluate the therapeutic role of these compounds are clearly required.

The endocannabinoid system in liver disease

Liver plays a major role in human homoeostasis with numerous functions, including regulation of lipid and carbohydrate metabolism, plasma protein synthesis, hormone production and detoxification. The emerging role of ECs in homoeostasis and lipid metabolism led several authors to investigate the interactions between the ECS and liver functions in normal and pathological conditions. The cannabinoid receptors are widely distributed on both hepatocytes and cholangiocytes, as on Kupffer and stellate cells, and their expression is modified during liver injury [110–113]. In particular, it was found that the ECS is involved in hepatic haemodynamic, cellular regeneration, liver fibrosis and lipid metabolism. As known, liver haemodynamic dysregulation plays a central role in cirrhosis, indeed portal hypertension and systemic vasodilation are involved in all major cirrhotic complications, such as ascites, variceal bleeding, liver-related cardiomyopathy and increased risk of cardiovascular events [114, 115]. Remarkably, the hypotensive effects of ECs, mainly mediated via CB1 activation,
have been associated with cirrhosis-induced vasodilation, and increased levels of AEA have been found in peripheral blood of patients with cirrhosis [116, 117]. In rodent models of cirrhosis, the administration of CB1 antagonist was found to decrease ascites and ameliorate sodium balance, and CB1 was shown to contribute to cardiac contractility alterations related to liver cardiomyopathy, suggesting that CB1 antagonists might be used to improve cardiovascular activity in cirrhosis [118, 119]. ECs have also been associated with fibrosis progression in HCV-infected patients, suggesting a profibrotic activity of ECs. Indeed, CB1 stimulation promotes the activity of myofibroblasts and stellate cells, likely via an increased TGF-β production [120, 121]. On the contrary, CB2 activation seems to play a protective role against fibrosis, promoting regeneration of liver cells after acute injury. Indeed, selective CB2 agonists have been found to slow fibrosis in a rat model of cirrhosis, and CB2 −/− knockout mice are more sensitive to acute liver injury, showing a low regenerative response [122, 123]. In summary, although ECs may worse cirrhosis progression and complications mainly via CB1 activation, specific CB2 agonists might slow liver fibrotic evolution.

Endocannabinoids in non-alcoholic fatty liver disease

The emblematic role of ECS in metabolic syndrome and obesity is already known; indeed, the CB1 antagonist rimonabant has been proposed in obesity treatment due to its beneficial effects on both body-weight and lipid profile. However, the neuropsychiatric adverse effects have limited the clinical use of this compound. Non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH) are strongly associated with metabolic syndrome, representing the ‘liver response’ to obesity, dyslipidaemia and altered carbohydrate metabolism. As ECs play a key role in liver lipid metabolism, a great interest is raised on effects of ECs on fatty liver diseases [124]. Cannabinoid receptors are involved in hepatic lipogenesis, inducing specific transcriptional factors, such as SREBPs (sterol regulatory element-binding proteins). Indeed in a mouse model with a selective deletion of hepatic CB1, a significant reduction in lipid storage during high-fat diet has been observed [125]. Intriguingly, also lipid profile and insulin resistance were improved; however, no effects on BMI have been registered in this murine model, suggesting that other mechanisms are involved in bodyweight regulation [125]. Altogether, these lines of evidence support the role of ECs in hepatic steatosis and fibrotic progression, opening the possibility of new therapeutic options in treatment of NAFLD and NASH; in particular, the efficacy and safety of the CB1 antagonist rimonabant are currently under investigation in a phase III clinical trial for treatment of NASH.

Conclusions

In the last years, accumulating lines of evidence have pointed out the homoeostatic role of the ECS in regulating intestinal motility, sensitivity and inflammation. An impairment of ECS signalling has been suggested to play a key role in several gastrointestinal disorders, such as FGIDs, IBDs and liver diseases. Even if conflicting results have been produced in vivo, convincing evidence suggests that pharmacological manipulation of this multifaceted system might provide new therapeutic options in treating GI diseases. The complexity and the redundancy of ECS make the manipulation of this complex system an appealing target for therapeutic purposes, although the possibility of central side effects strongly limited the current use of these compounds in clinical settings. Using peripherally acting drugs with no affinity on central cannabinoid receptors is an intriguing strategy, and as PEA formulations are already available for the treatment of chronic pain, further in vivo studies to test the clinical efficacy of these compounds are strongly warranted.

Conflict of interest

The authors have no conflicting interests to declare.

References

11. Lambert DM, Muccioli GG. Endocannabi- noids and related N-acylethanolamines in the control of appetite and energy...


Cannabinoid type 1 receptor modulates intestinal propulsion by an attenuation of intestinal motor responses within the myenteric part of the peristaltic reflex. *Neurogastroenterol Motil.* 2007; 19: 744–53.


